- Home
- ACHV vs NTHI Comparison
ACHV vs NTHI Comparison
Compare ACHV & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- NTHI
- Stock Information
- Founded
- ACHV N/A
- NTHI 2008
- Country
- ACHV United States
- NTHI United States
- Employees
- ACHV N/A
- NTHI N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- NTHI Health Care
- Exchange
- ACHV Nasdaq
- NTHI Nasdaq
- Market Cap
- ACHV 131.3M
- NTHI 155.4M
- IPO Year
- ACHV N/A
- NTHI N/A
- Fundamental
- Price
- ACHV $3.08
- NTHI $10.49
- Analyst Decision
- ACHV Strong Buy
- NTHI
- Analyst Count
- ACHV 2
- NTHI 0
- Target Price
- ACHV $16.00
- NTHI N/A
- AVG Volume (30 Days)
- ACHV 1.6M
- NTHI 82.3K
- Earning Date
- ACHV 11-06-2025
- NTHI 08-19-2025
- Dividend Yield
- ACHV N/A
- NTHI N/A
- EPS Growth
- ACHV N/A
- NTHI N/A
- EPS
- ACHV N/A
- NTHI N/A
- Revenue
- ACHV N/A
- NTHI $59,990.00
- Revenue This Year
- ACHV N/A
- NTHI N/A
- Revenue Next Year
- ACHV N/A
- NTHI N/A
- P/E Ratio
- ACHV N/A
- NTHI N/A
- Revenue Growth
- ACHV N/A
- NTHI N/A
- 52 Week Low
- ACHV $1.84
- NTHI $3.20
- 52 Week High
- ACHV $5.31
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- ACHV 56.04
- NTHI N/A
- Support Level
- ACHV $2.68
- NTHI N/A
- Resistance Level
- ACHV $3.30
- NTHI N/A
- Average True Range (ATR)
- ACHV 0.25
- NTHI 0.00
- MACD
- ACHV 0.02
- NTHI 0.00
- Stochastic Oscillator
- ACHV 49.38
- NTHI 0.00
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").